Literature DB >> 18684196

Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study.

Winston Dunn1, Ronghui Xu, Deborah L Wingard, Christopher Rogers, Paul Angulo, Zobair M Younossi, Jeffrey B Schwimmer.   

Abstract

OBJECTIVE: Case series suggest that nonalcoholic fatty liver disease (NAFLD) is associated with increased all-cause and cardiovascular mortality. The current study compared the survival of subjects with and without suspected NAFLD in a population-based cohort, and placed the finding in the context of previously published case series.
METHODS: Primary analysis assessed mortality for NHANES-III participants with and without suspected NAFLD using the National Death Index. Suspected NAFLD was based upon unexplained ALT elevation. The Olmsted County and Cleveland Clinic case series were also used for comparison. Survivals were compared using Proportional Hazards Model and direct age standardization.
RESULTS: The NHANES cohort included 980 with and 6,594 subjects without suspected NAFLD. Over a mean of 8.7 yr, suspected NAFLD had a hazards ratio of 1.37 (95% CI 0.98-1.91) for all-cause mortality. In the 45-54 age group, suspected NAFLD had significantly higher all-cause (4.40 95% CI 1.27-13.23) and cardiovascular mortality (8.15, 95% CI 2.00-33.20) after adjusting for conventional cardiovascular risk factors. The age-standardized rate per 10,000 per year was 129 (95% CI 118-140) for the NHANES non-NAFLD cohort, 154 (95% CI 116-198) for the NHANES suspected NAFLD cohort, 214 (95% CI 157-279) for the Olmsted County series, and 426 (95% CI 298-573) for the Cleveland Clinic series.
CONCLUSION: The magnitude of mortality risk in NAFLD depends on the setting and method of ascertainment. Suspected NAFLD in the 45-54 age group is a strong independent risk factor for cardiovascular death and warrants further cardiovascular risk management guidelines.

Entities:  

Mesh:

Year:  2008        PMID: 18684196      PMCID: PMC2574666          DOI: 10.1111/j.1572-0241.2008.02034.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  29 in total

1.  Liver fibrosis in overweight patients.

Authors:  V Ratziu; P Giral; F Charlotte; E Bruckert; V Thibault; I Theodorou; L Khalil; G Turpin; P Opolon; T Poynard
Journal:  Gastroenterology       Date:  2000-06       Impact factor: 22.682

2.  Elevated AST or ALT to nonalcoholic fatty liver disease: accurate predictor of disease prevalence?

Authors:  Andy S Yu; Emmet B Keeffe
Journal:  Am J Gastroenterol       Date:  2003-05       Impact factor: 10.864

3.  Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults.

Authors:  Chien-Hua Chen; Min-Ho Huang; Jee-Chun Yang; Chiu-Kue Nien; Chi-Chieh Yang; Yung-Hsiang Yeh; Sen-Kou Yueh
Journal:  J Clin Gastroenterol       Date:  2006-09       Impact factor: 3.062

4.  One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation.

Authors:  Charlotte K Ryan; Lesley A Johnson; Barbara I Germin; Amadeo Marcos
Journal:  Liver Transpl       Date:  2002-12       Impact factor: 5.799

5.  Detection of insulin resistance by simple quantitative insulin sensitivity check index QUICKI for epidemiological assessment and prevention.

Authors:  Jirí Hrebícek; Vladimír Janout; Jana Malincíková; Dagmar Horáková; Ludek Cízek
Journal:  J Clin Endocrinol Metab       Date:  2002-01       Impact factor: 5.958

6.  Long-term follow-up of patients with NAFLD and elevated liver enzymes.

Authors:  Mattias Ekstedt; Lennart E Franzén; Ulrik L Mathiesen; Lars Thorelius; Marika Holmqvist; Göran Bodemar; Stergios Kechagias
Journal:  Hepatology       Date:  2006-10       Impact factor: 17.425

7.  Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology.

Authors:  M M Skelly; P D James; S D Ryder
Journal:  J Hepatol       Date:  2001-08       Impact factor: 25.083

8.  Updated definitions of healthy ranges for serum alanine aminotransferase levels.

Authors:  Daniele Prati; Emanuela Taioli; Alberto Zanella; Emanuela Della Torre; Sonia Butelli; Emanuela Del Vecchio; Luciana Vianello; Francesco Zanuso; Fulvio Mozzi; Silvano Milani; Dario Conte; Massimo Colombo; Girolamo Sirchia
Journal:  Ann Intern Med       Date:  2002-07-02       Impact factor: 25.391

9.  Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States.

Authors:  Constance E Ruhl; James E Everhart
Journal:  Gastroenterology       Date:  2003-01       Impact factor: 22.682

10.  The prevalence and etiology of elevated aminotransferase levels in the United States.

Authors:  Jeanne M Clark; Frederick L Brancati; Anna Mae Diehl
Journal:  Am J Gastroenterol       Date:  2003-05       Impact factor: 10.864

View more
  119 in total

Review 1.  Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy.

Authors:  Scott B Reeder; Irene Cruite; Gavin Hamilton; Claude B Sirlin
Journal:  J Magn Reson Imaging       Date:  2011-09-16       Impact factor: 4.813

2.  Withholding statins in patients with underlying liver disease: wise or unwise?

Authors:  Robert P Perrillo
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-04

Review 3.  Quantification of liver fat with magnetic resonance imaging.

Authors:  Scott B Reeder; Claude B Sirlin
Journal:  Magn Reson Imaging Clin N Am       Date:  2010-08       Impact factor: 2.266

Review 4.  Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Melanie D Beaton
Journal:  Can J Gastroenterol       Date:  2012-06       Impact factor: 3.522

5.  Development and Validation of an Algorithm to Identify Nonalcoholic Fatty Liver Disease in the Electronic Medical Record.

Authors:  Kathleen E Corey; Uri Kartoun; Hui Zheng; Stanley Y Shaw
Journal:  Dig Dis Sci       Date:  2015-11-04       Impact factor: 3.199

6.  Nonalcoholic fatty liver disease is associated with coronary artery calcification.

Authors:  Donghee Kim; Su-Yeon Choi; Eun Ha Park; Whal Lee; Jin Hwa Kang; Won Kim; Yoon Jun Kim; Jung-Hwan Yoon; Sook Hyang Jeong; Dong Ho Lee; Hyo-suk Lee; Joseph Larson; Terry M Therneau; W Ray Kim
Journal:  Hepatology       Date:  2012-07-02       Impact factor: 17.425

7.  The relationship between arterial stiffness and nonalcoholic fatty liver disease.

Authors:  Yong-Jae Lee; Jae-Yong Shim; Byung-Soo Moon; Youn-Ho Shin; Dong-Hyuk Jung; Jung-Hyun Lee; Hye-Ree Lee
Journal:  Dig Dis Sci       Date:  2011-07-13       Impact factor: 3.199

Review 8.  Nonalcoholic fatty liver disease.

Authors:  Sandra K Erickson
Journal:  J Lipid Res       Date:  2008-12-12       Impact factor: 5.922

9.  Nonalcoholic fatty liver disease (NAFLD): is it really a serious condition?

Authors:  Julia Wattacheril; Naga Chalasani
Journal:  Hepatology       Date:  2012-10       Impact factor: 17.425

Review 10.  Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease.

Authors:  Stefano Ballestri; Amedeo Lonardo; Stefano Bonapace; Christopher D Byrne; Paola Loria; Giovanni Targher
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.